Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
- Submitting institution
-
University of Keele
- Unit of assessment
- 12 - Engineering
- Output identifier
- 395
- Type
- D - Journal article
- DOI
-
10.1089/scd.2017.0172
- Title of journal
- Stem Cells and Development
- Article number
- -
- First page
- 1695
- Volume
- 26
- Issue
- 23
- ISSN
- 1547-3287
- Open access status
- Compliant
- Month of publication
- October
- Year of publication
- 2017
- URL
-
https://www.liebertpub.com/doi/full/10.1089/scd.2017.0172
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
6
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- The study explored the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to assess the impact of different drugs on function associated with genetic perturbation of the HERG ion channel. hiPSC-CMs derived from Long QT syndrome patients (LQTS-hiPSC-CMs) demonstrated their utility in testing efficacy of current and potential therapeutics in an in vitro platform, paving way for PPARδ agonists as a promising line of treatment for LQTS patients. Funding support was provided by British Heart Foundation (RG/15/6/31436/BHF), NC3Rs (NC/K000225/1) and MRC (MR/M017354/1/MRC). A component of this work was included in the successfully defended PhD thesis of G. Duncan.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
